Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing.[1] In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.[2][3]

References

  1. ^ McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, et al. (March 2010). "Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor". J. Med. Chem. 53 (6): 2443–63. doi:10.1021/jm9015526. PMID 20163176.
  2. ^ "First recommendation for HCV drug vaniprevir, in Japan". datamonitorhealthcare.com. September 25, 2014.
  3. ^ "New Drugs Approved" (PDF). Pharmaceuticals and Medical Devices Agency. Archived from the original (PDF) on 2015-05-13. Retrieved 2015-08-22.
Allikas: https://en.wikipedia.org/wiki/Vaniprevir
No tags for this post.